BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
BAYRY Outperforms Industry, Sector & S&P 500 Index
While challenges in its Crop Science business and litigations have bogged down investors in the past couple of years, 2025 has proved to be a turnaround for Bayer.
The impressive performance can be attributed to new drug approvals and encouraging pipeline progress.
Let's delve further into BAYRY's strengths and weaknesses to analyze how to play the stock at present.
BAYRY's Efforts to Strengthen Pharma Business
Bayer's new products, such as prostate cancer drug Nubeqa and kidney disease drug Kerendia (finerenone), continue to maintain their impressive momentum in the Pharmaceutical division and offset the negative impact of a decline in Xarelto sales.
The FDA recently approved a label expansion of the kidney disease drug Kerendia. The regulatory body approved finerenone for the treatment of adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%.
With the latest FDA approval, Kerendia has become the only non-steroidal mineralocorticoid receptor antagonist approved in the United States for chronic kidney disease associated with type 2 diabetes and for HF with LVEF of ≥40%.
Last month, the FDA also expanded Nubeqa's label for a third indication for patients with advanced prostate cancer. Following this approval, Nubeqa is the first FDA-approved androgen receptor inhibitor for the treatment of patients with hormone-sensitive prostate cancer, in combination with androgen deprivation therapy, with or without chemotherapy.
In addition, Nubeqa is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer, who are at high risk of developing metastatic disease.
We remind investors that Nubeqa achieved blockbuster status in 2024, with annual sales reaching €1.52 billion for full-year 2024.
BAYRY expects to launch two new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain type of heart disease.
Elinzanetant was recently approved in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause under the brand name Lynkuet. Elinzanetant is under regulatory review in the United States, countries of the European Union and other markets around the world for VMS.
Bayer recently submitted a marketing authorization application to the European Medicines Agency for its investigational contrast agent gadoquatrane for contrast enhancement in magnetic resonance imaging to detect and visualize known or suspected pathologies in all body regions and the central nervous system in adults and pediatric patients, including neonates.
A new drug application has also been submitted to the FDA for gadoquatrane for the above-mentioned indication.
The European Commission has also granted a label extension for Eylea (aflibercept 8 mg, 114.3 mg/ml solution for injection) with extended treatment intervals of up to 6 months for the treatment of two major retinal diseases, neovascular (wet) age-related macular degeneration and visual impairment due to diabetic macular edema.
Please note that Bayer's HealthCare unit co-develops Eylea with Regeneron REGN, which records net product sales of Eylea in the United States. BAYRY records net product sales of Eylea outside the country. REGN records its share of profits/losses in connection with the sales of Eylea outside the United States.
Bayer also has a collaboration agreement with Johnson & Johnson JNJ for oral anticoagulant Xarelto. The drug is marketed by J&J. Bayer earns license revenues from JNJ for Xarelto sales in the United States.
The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired the clinical-stage biopharmaceutical company Vividion Therapeutics to expand its presence in precision small-molecule therapeutics, with a primary focus on oncology and immunology.
BAYRY has expanded its pipeline in new modalities of cell therapy through the acquisition of BlueRock, and in gene therapy, through the AskBio buyout.
Cost-Cutting Measures Should Boost BAYRY's Earnings
Bayer has implemented a new operating model to reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes. The company is also undertaking significant job cuts. These efforts should help the company cut costs.
BAYRY's Valuation and Estimates
From a valuation perspective, BAYRY is currently quite inexpensive. Going by the price/earnings ratio, the company's shares currently trade at 5.90X forward earnings, quite below 15.16X for the industry. The stock is trading below its five-year mean of 6.94X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has risen from $1.25 to $1.30 while that for 2026 has increased from $1.31 to $1.35 over the past 60 days.
Invest in BAYRY
Pharma bigwigs are mostly considered safe havens for investors interested in this sector. BAYRY has one of the most diversified portfolios in the industry. The pharma business continues to march ahead. Newer drugs pave the way for growth, and the approval of additional new drugs should further bolster the portfolio.
New launches in the Consumer Health business are a positive.
While challenges for the Crop Science business and significant Roundup litigation charges continue to be a headwind, the company's recent upbeat performance provides distressed investors with a ray of hope.
We recommend the stock to investors at current levels as we believe the worst is most likely behind BAYRY and the company is poised for a turnaround hereafter.
BAYRY currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.
Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Think It's Too Late to Buy This Leading Industrials Stock? Here's the Biggest Reason Why There's Still Time
Key Points The company's revenue expectations keep improving through 2025. Only increased costs in connection with tariffs are holding back profit increases over the near term. 10 stocks we like better than Vertiv › The stock for data center infrastructure company and Nvidia partner Vertiv (NYSE: VRT) is trading up 84% since the end of March. That growth could continue as the company's underlying momentum is being masked by the effect of tariffs and an acceleration in investment to fuel future growth. Vertiv's quiet growth burst The table below shows the progression of its full-year guidance in 2025. Vertiv's sales guidance outstrips its adjusted operating profit increases. Profit growth is lagging sales growth due to extra costs associated with tariffs and the pull-forward of investment in research and development to fuel growth. Vertiv In February In April In July Increase in Guidance from February to July* Sales guidance $9.125 million to $9.175 million $9.325 million to $9.575 million $9.925 million to $10.075 million 8.7% Adjusted operating profit $1.910 million to $1.960 million $1.885 million to $1.985 million $1,950 million to $2.030 million 2.8% Free cash flow $1.275 million to $1.325 million $1.250 million to $1.350 million $1.375 million to $1.425 million 7.7% Data source: Vertiv, author's analysis. *All figures calculated assuming the midpoint of guidance. In usual circumstances, it's reasonable to expect a company's operating profit to expand more than its revenue growth. Margins should improve in a manufacturing company when it has larger volumes due to the benefits of scale, such as increased production efficiency and lower fixed cost per unit production. However, provided the tariff environment doesn't worsen for Vertiv, future orders and revenue increases are likely to translate into significant increases in profits and cash flow. Where next for Vertiv? Momentum continues to build in the data center end market, driven by torrid growth in artificial intelligence application demand. As such, Vertiv is in the early innings of a multi-year expansion in data center spending, and that includes its involvement in developing power systems and solutions for the next generation of data centers with Nvidia. Vertiv has a bright future, and it's not too late to invest in it. Should you invest $1,000 in Vertiv right now? Before you buy stock in Vertiv, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertiv wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,076% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy.
CTV News
an hour ago
- CTV News
Lawyer argues Meta can't be held liable for gunmaker's Instagram posts in Uvalde families' lawsuit
Crosses are surrounded by flowers and other mementos at a memorial, June 9, 2022, for the victims of a shooting at Robb Elementary School in Uvalde, Texas. (AP Photo/Eric Gay, File) LOS ANGELES — A lawsuit filed by families of the Uvalde school shooting victims alleging Instagram allowed gun manufacturers to promote firearms to minors should be thrown out, lawyers for Meta, Instagram's parent company, argued Tuesday. Nineteen children and two teachers were killed in the May 2022 shooting at Robb Elementary School in Uvalde, Texas. The families sued Meta in Los Angeles in May 2024, saying the social media platform failed to enforce its own rules forbidding firearms advertisements aimed at minors. The families, who were present at last month's hearing, did not appear in court, with a lawyer citing the back-to-school season. Many plaintiffs attended the hearing virtually, he said. In one ad posted on Instagram, the Georgia-based gunmaker Daniel Defense shows Santa Claus holding an assault rifle. In another post by the same company, a rifle leans against a refrigerator, with the caption: 'Let's normalize kitchen Daniels. What Daniels do you use to protect your kitchen and home?' The lawsuit alleges those posts are marketed toward minors. The Uvalde gunman opened an online account with Daniel Defense before his 18th birthday and purchased the rifle as soon as he could, according to the lawsuit. He also owned various Instagram accounts and had an 'obsessive relationship' with the platform, at times opening the app more than 100 times a day, plaintiffs' lawyers found in an analysis of the shooter's phone. Plaintiffs say minors can access gun content on Instagram Meta attorney Kristin Linsley argued that the families provided no proof that minors, including the Uvalde gunman, even read the Daniel Defense posts on Instagram. She also said the posts didn't violate Meta's policies because they weren't direct advertisements and did not include links to purchase any products. Katie Mesner-Hage, representing the victims' families, said the defence's claim is 'fundamentally unfair,' as the plaintiffs don't have access to Meta data that would indicate whether the shooter encountered those posts. She added that if the content had landed on the shooter's feed, as the plaintiffs allege, then Meta 'not only knew about it, they designed the system so it would be delivered to him.' 'They knew more about him than anyone else on the planet,' she said. Linsley said content advertising firearms for sale on Instagram is allowed if posted by 'brick-and-motor and online retailers,' but visibility of those posts was restricted for minors under Meta's advertising policies from the end of 2021 to October 2022. 'This is not a playbook for how to violate the rules. This is actually what the rules are,' Linsley said. The plaintiff's team, however, showed a fake profile they created for a 17-year-old boy earlier this month, through which they were able to search Daniel Defense's Instagram account and see a post that included a picture of a gun, as well as a link to the gun manufacturer's website. When the link was clicked, the gun-maker's website opened, and the team was able to select a firearm and add it to their cart, all within Instagram's app — an experiment that refutes Meta's assertion that posts relating to firearms aren't visible to users under 21, Mesner-Hage said. Linsley said in her rebuttal that the experiment was done this year and not in 2021 to 2022, which is when the policy she described was in effect. The families have also sued Daniel Defense and video game company Activision, which produces 'Call of Duty.' Case hinges on social media's responsibility for content creation Linsley said the Communications Decency Act allows social media platforms to moderate content without being treated as publishers of that content. 'The only response a company can have is to not have these kinds of rules at all,' Linsley said. 'It just gets you down a rabbit hole very quickly.' Mesner-Hage argued Meta is not protected by the act because social media platforms don't just host speech, but help curate it through its algorithms. Daniel Defense, she said, didn't have to pay for ads to get free access to Meta's analytical data through its business account on Instagram. That data shows the company which age bracket and gender engaged most with a specific post. 'Daniel Defense is not on Instagram to make friends. ... They're on there to promote their product,' Mesner-Hage said. 'It's not a paid advertisement, but I would struggle to describe this as anything other than an advertisement.' The lawsuit alleges that firearm companies tweaked their online marketing to comply with Meta's policies, including by avoiding the words 'buy' or 'sell' and not providing links to purchase, and that the social media company did not protect users against such strategies. Last month, lawyers for Activision also argued that legal proceedings against them should be thrown out, saying the families allegations are barred by the First Amendment. The families alleged that the war-themed video game Call of Duty trained and conditioned the Uvalde gunman to orchestrate his attack. Lawyers for the plaintiffs asked the judge to allow them to amend their lawsuit with the new information they presented Tuesday before ruling on the defence's motion. The defence claimed that was unnecessary, as the case would not have merit even with the amendments. The judge has yet to rule on Activision's motion and did not immediately rule on the Meta case. Itzel Luna, The Associated Press
National Post
an hour ago
- National Post
The biggest winner of the Trump-Putin summit might be this Alaska man
An Alaska man might have walked away as the biggest winner of last week's high stakes summit between U.S. President Donald Trump and Russian President Vladimir Putin in Anchorage. He rode off with a new motorcycle, courtesy of the Russian government. Article content Putin's delegation gifted Mark Warren, a retired fire inspector for the Municipality of Anchorage, a Ural Gear Up motorcycle with a sidecar, one week after a television crew's interview with Warren went viral in Russia. The motorcycle company, founded in 1941 in western Siberia, now assembles its bikes in Petropavlovsk, Kazakhstan, and distributes them through a team based in Woodinville, Washington. Article content Article content Article content Warren already owned one Ural motorcycle, purchased from a neighbour. He was out running errands on it a week before the summit when a Russian television crew saw him and asked for an interview. Article content Article content 'It went viral, it went crazy, and I have no idea why, because I'm really just a super-duper normal guy,' Warren said Tuesday. 'They just interviewed some old guy on a Ural, and for some reason they think it's cool.' Article content On Aug. 13, two days before the Trump-Putin summit to discuss the war in Ukraine, Warren received a call from the Russian journalist, who told him, 'They've decided to give you a bike.' Article content Warren said a document he received indicated the gift was arranged through the Russian Embassy in the U.S., which did not immediately return a message Tuesday. Article content Warren said he initially thought it might be a scam. But after Putin and Trump departed Joint Base Elmendorf-Richardson following their three-hour summit last Friday, he got another call informing him the bike was at the base. Article content Article content He was directed to go to an Anchorage hotel the next day for the handoff. He went with his wife, and there in the parking lot, along with six men he assumed to be Russians, was the olive-green motorcycle, valued at $22,000. Article content Article content 'I dropped my jaw,' he said. 'I went, 'You've got to be joking me.'' Article content All the Russians asked in return was to take his picture and interview him, he said: 'If they want something from me, they're gonna be sorely disappointed.' Article content Two reporters and someone from the consulate jumped on the bike with him, and he drove slowly around the parking lot while a cameraman ran alongside and filmed it. Article content The only reservation he had about taking the Ural is that he might somehow be implicated in some nefarious Russian scheme. Warren said he doesn't want a 'bunch of haters coming after me that I got a Russian motorcycle. … I don't want this for my family.' Article content When he was signing the paperwork taking ownership of the motorcycle from the Russian embassy, he noticed it was manufactured Aug. 12. Article content 'The obvious thing here is that it rolled off the showroom floor and slid into a jet within probably 24 hours,' he said. Article content
